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Abstract
Background: Migraine headaches both with and without aura vary in frequency, duration and intensity,
affecting the quality of life of up to 10% of the total population. Migraines are treated with both prophylactic
and acute medications. Patent foramen ovale (PFO) is one likely cause of migraine headaches and this is
present in up to 25% of the total population. Percutaneous PFO closure is a likely option for definitive
treatment for migraine. Once proven refractory to medical treatment, do patients with PFO and migraine
respond to percutaneous PFO closure to reduce the frequency, duration and intensity of migraine headaches?
Methods: An exhaustive search of available medical literature was conducted using Medline/Ovid, CINAHL
and Evidence-Based Medicine Reviews Multifile using the keywords: patent foramen ovale, migraine
disorders, therapeutics and refractory. Inclusion criteria consisted of participants with a known patent
foramen ovale and migraine headaches refractory to medical treatment, as well as studies performing
percutaneous PFO closure measuring cessation or reduction in frequency, duration and intensity of migraine
headaches. All articles were assessed for quality using GRADE.
Results: One randomized controlled trial, three prospective observational studies and one retrospective
observational study fit the inclusion criteria. All observational studies demonstrated resolution of migraine
with aura along with improved migraine symptomology in MIDAS score, frequency, duration and intensity of
migraines. However the only randomized controlled trial (RCT) to date demonstrated no resolution of
migraine headaches after six months. No other endpoints were measured such as frequency, duration or
intensity. Many complications, both minor and serious, resulted in this RCT. After GRADE assessment, the
RCT was determined to be high validity and all observational studies very low validity.
Conclusion: Four observational studies show some benefit to percutaneous PFO closure as treatment for
refractory migraine headaches. However, one randomized controlled trial shows no benefit, unable to meet its
endpoints. At this time, a recommendation cannot be made for percutaneous PFO closure in patients with
refractory migraine headaches until further RCTs are performed and improvements are made in future
studies.
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Abstract   
 
Background:  Migraine headaches both with and without aura vary in frequency, duration and 
intensity, affecting the quality of life of up to 10% of the total population.  Migraines are treated 
with both prophylactic and acute medications.  Patent foramen ovale (PFO) is one likely cause of 
migraine headaches and this is present in up to 25% of the total population.  Percutaneous PFO 
closure is a likely option for definitive treatment for migraine.  Once proven refractory to medical 
treatment, do patients with PFO and migraine respond to percutaneous PFO closure to reduce the 
frequency, duration and intensity of migraine headaches? 
Methods:  An exhaustive search of available medical literature was conducted using 
Medline/Ovid, CINAHL and Evidence-Based Medicine Reviews Multifile using the keywords: 
patent foramen ovale, migraine disorders, therapeutics and refractory.  Inclusion criteria consisted 
of participants with a known patent foramen ovale and migraine headaches refractory to medical 
treatment, as well as studies performing percutaneous PFO closure measuring cessation or 
reduction in frequency, duration and intensity of migraine headaches.  All articles were assessed 
for quality using GRADE. 
Results:  One randomized controlled trial, three prospective observational studies and one 
retrospective observational study fit the inclusion criteria.  All observational studies demonstrated 
resolution of migraine with aura along with improved migraine symptomology in MIDAS score, 
frequency, duration and intensity of migraines.  However the only randomized controlled trial 
(RCT) to date demonstrated no resolution of migraine headaches after six months.  No other 
endpoints were measured such as frequency, duration or intensity.  Many complications, both 
minor and serious, resulted in this RCT.  After GRADE assessment, the RCT was determined to 
be high validity and all observational studies very low validity. 
Conclusion:  Four observational studies show some benefit to percutaneous PFO closure as 
treatment for refractory migraine headaches.  However, one randomized controlled trial shows no 
benefit, unable to meet its endpoints.  At this time, a recommendation cannot be made for 
percutaneous PFO closure in patients with refractory migraine headaches until further RCTs are 
performed and improvements are made in future studies. 
Keywords:  patent foramen ovale, migraine disorders, therapeutics, refractory 
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Percutaneous Closure of Patent Foramen Ovale for the Treatment of Refractory 
Migraine Headaches 
BACKGROUND 
 Migraine headaches can be debilitating and affect quality of life on a daily basis.  
It is estimated that migraines affect 13% of the total population,1 largely affecting more 
females than males. About 36% of migraines are preceded by aura.2  There are numerous 
medical treatments that can combat the effects of migraine headaches.  Preventive 
medications include beta blockers, antidepressants, anticonvulsants and calcium channel 
blockers.  Acute medications include triptans, acetyl salicylic acid (ASA), non-steroidal 
anti-inflammatory drugs (NSAIDS), paracetamol, ergotamines, caffeine, opioids and 
antiemetics.  There are many options to treat a migraine, but some patients can be 
refractory to medical treatment, having tried at least 2 different medications without 
success, either because they cannot tolerate or do not respond to them.  It is not cost 
effective or efficient to try every option in every class. 
 A connection has been proven between migraine headaches and patent foramen 
ovale (PFO), especially with migraine with aura.3,4  There is a 25% prevalence of patent 
foramen ovale in the general population and there are no known causes or risk factors.5  
In a 2000 study, Wilmshurst and Nightingale6 stated, “that in some migraine patients, 
venous blood contains agents normally removed by passage through the lungs that can 
trigger an attack of migraine if they reach the brain in sufficient concentrations; 
alternatively, long-term shunting [through the PFO] of the agents may reduce the 
threshold for migraine generation in the brain.”6  In patients with a PFO and migraine 
headache (HA) refractory to medical treatment, does percutaneous closure of the PFO 
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reduce the frequency, duration and intensity of migraine headaches?  If proven to do so, 
percutaneous PFO closure could be a definitive treatment for refractory migraine and 
substantial improvement in quality of life. 
METHODS 
 An exhaustive search was performed using three different search engines.  A 
search of Medline/Ovid was performed using the search terms: patent foramen ovale, 
migraine disorders, therapeutics and refractory.  A search of CINAHL and Evidence-
Based Medicine Reviews Multifile was performed using the search terms: patient 
foramen ovale, migraine and refractory.  Furthermore, a search of references of relevant 
articles was conducted in order to find additional studies.  Critical appraisal of each 
article included was performed for validity, risk of bias and other criteria using the 
Grading of Recommendations, Assessment, Development and Evaluation (GRADE).7           
Inclusion criteria consisted of patients with a patent foramen ovale and migraine 
headaches proven refractory to medications, percutaneous transcatheter PFO closure and 
outcomes measuring cessation or reduction in frequency, duration and intensity of 
migraine headache.  Exclusion criteria consisted of PFO closure for reasons other than 
migraine headache (cryptogenic stroke, transient ischemic attack, previous cardiac or 
cerebral events) or lack of enrolled participants proven refractory to migraine medical 
treatment.  
RESULTS 
 The extensive search of three different databases yielded a total of fifteen articles.  
Only five studies met inclusion criteria, one randomized controlled trial (RCT)8 and four 
8 
 
observational studies, three of which were prospective9-11 and one of which was 
retrospective.12 
Other similar systematic reviews13,14 have been performed on the connection 
between PFO and migraine, although inclusion criteria did not specify whether a patient 
was refractory to medical treatment.  The most recent systematic review13 from 2010 
addressed the role of percutaneous PFO closure on migraine occurrence.  A total of 11 
studies were included with 1,306 participants.  Of those receiving PFO closure, only 40% 
suffered from migraine headaches while the remaining suffered from other events, such 
as ischemic stroke or transient ischemic attack (TIA).  Results indicated complete 
migraine resolution in 46% with significant migraine improvement in 83%.  This 
systematic review13 indicates a benefit of migraine symptomatology from PFO closure, 
although “many questions remain unsolved.”13 
 Many other studies have been conducted on PFO closure and migraine incidence, 
although many of them assess migraine as secondary prevention for paradoxical 
embolism and risk of stroke. 
MIST Trial 
 This randomized, double-blind, controlled trial8 assessed 432 participants.  Of 
these, 163 were found to have a moderate to large right to left shunt (RLS).  The 
remaining participants were excluded based on finding of a small or absent RLS.  One 
hundred and forty-seven participants (124 female, 23 male) were randomized either to 
implant for PFO closure or to undergo sham procedure approved by a multi-center 
research ethics committee.  Those in the cardiac catheterization laboratory, who were 
required to perform the procedure, were the only ones who knew the true treatment 
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allocation.  Twenty-four hours prior to the procedure, all participants were given ASA 
300 mg plus clopidogrel 300 mg.  All participants also received general anesthesia plus 
transesophageal echocardiogram (TEE).  The implant group received the STARFlex 
septal repair implant and heparin 100 IU/kg.8 
Inclusion criteria consisted of adults aged 18-60 years old with migraine 
headaches occurring five or more times per month, having at least 7 headache-free days 
per month, having failed two or more types of prophylactic medications, having failed on 
average greater than two acute medications and have a moderate to large RLS consistent 
with PFO.  Exclusion criteria consisted of those with cardiologic, hematologic or 
neurologic disorders; or those who were pregnant.8 
From the 147 randomized participants, 136 completed treatment, either PFO 
closure or the sham procedure.  The primary outcome measured migraine headache 
cessation 91 to 180 days post procedure through a headache diary.  Only 6 participants 
achieved migraine cessation, 3 from each group (P = 0.51).  Secondary endpoints 
measured changes in severity, frequency, character and quality of life through the 
Migraine Disability Assessment Score (MIDAS), Headache Impact Test (HIT-6) and 
Short Form 36 quality of life questionnaire (SF-36v2) assessments.  There was no 
statistical difference between resulting data of the implant and sham groups.  There was 
no resolution of migraine attacks (CI -6.50-7.42, P = 1.0).  Frequency of migraine attacks 
per month did not decrease (CI -0.15-1.08, P = 0.13).  Total MIDAS score remained 
virtually the same (CI -10-10, P = 0.89).  Total HIT-6 score remained virtually the same 
(CI -5-6, P = 0.85).  The primary and secondary endpoints were not achieved.8 
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Complications were prevalent in this study with most participants experiencing 
minor adverse events and 16 participants experiencing serious adverse events, such as 
pericardial effusion, cardiac tamponade, retroperitoneal bleed, incision site bleed, anemia, 
nose bleed, stroke and others.  Whether or not complications were worse in one group 
than the other is not stated.8 
The healing phase ended at day 90 and the analysis phase ended at day 180.  
Follow up concluded at day 180, or at 6 months.  Only one participant was lost to follow 
up while one participant was missing baseline diary cards and thus not included in the 
resulting data.  A transthoracic echocardiogram (TTE) was performed at the end of the 
analysis phase where a residual shunt was found in 4 participants.  The MIDAS 
assessment was given at baseline, at the end of the healing phase and at the end of the 
analysis phase.  Each participant was required to attend a headache clinic six times at 
intervals of 30 days +/- 7 days.8 
Rigatelli et al, 2010  
 This prospective short term observational study9 included a total of 86 
participants.  Forty participants received percutaneous PFO closure based on a MIDAS 
class of 3-4 while the remaining 46 received medical treatment based on a MIDAS class 
of 1-2.  Because of division based on MIDAS class, no randomization was involved.  Of 
the 40 receiving PFO closure, 34 were female, 6 were male, 34 of the 40 had 
accompanying aura and the average age was 35 +/- 6.7 years.  The setting was performed 
in a single center.  Closure of the PFO was performed using one of three device implants: 
Amplatzer Occluder family, Premere Closure System or Biostar.  The procedure was 
guided by echocardiography.  The group receiving PFO closure was compared to the 
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medical treatment group, although it did not serve as a true control group since no direct 
comparisons or calculations were made.  Inclusion criteria consisted of adults with 
migraine headaches refractory to medical treatment, migraine with or without aura, RLS 
consistent with PFO, anatomic and functional characteristic predisposing to paradoxical 
embolism with cerebral ischemia, interarterial septal aneurysm (ISA), Eustachian valve and 
coagulation abnormalities.9 
 The primary outcome showed 100% of the participants experienced improvement 
of their symptoms.  Secondary outcomes showed improvement in MIDAS score of 8.3 
+/- 7.8 and 100% of those with auras no longer experienced them.  In the medical 
treatment class, the MIDAS remained virtually the same, from 22.6 +/- 7.1 at baseline to 
19.1 +/- 8.2.  There were no major or adverse complications.9 
 Follow up continued for a minimum of 6 months with a mean of 29.2 +/- 14.8 
months.  At one month, a TEE, a TTE, and a transcranial Doppler (TC-D) were 
performed along with the use of a holter monitor and subsequent clinic visit.  At 6 
months, a TTE was performed with an additional TEE if a shunt was detected.  A clinic 
visit and MIDAS assessment were also required for these individuals.  This was repeated 
at 12 months.  The MIDAS assessment was continued yearly thereafter.  Closure of the 
PFO was found to be complete in 95% with a persistent small shunt in 2 participants.9 
Rigatelli et al, 2012 
 This prospective long term observational study10 included 80 participants, 58 
female, 22 male and 63 of the total with aura.  The average age was 38.9 +/- 5.8 years.  It 
was performed in a single center.  Closure of the PFO was performed with one of three 
device implants: Amplatzer Occluder family, Premere Closure System or Biostar.  The 
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procedure was guided by echocardiography.  No comparison or sham procedure was 
performed.  Inclusion criteria consisted of adults with migraine headaches refractory to 
medical treatment, migraine with or without aura, RLS consistent with PFO, anatomic 
and functional characteristics predisposing to paradoxical embolism, ISA, Eustachian 
valve and coagulation abnormalities.10 
 The primary outcome showed improvement in migraine symptomatology in 70 
participants.  Secondary outcomes showed improvement in MIDAS score of 33.4 +/- 6.7 
to 10.6 +/- 9.8.  There was no improvement in 12.5% of participants while auras were 
cured in 61 out of the 63 patients.  There was no worsening in migraine symptomology in 
any participant and no major or adverse complications were observed.10 
 Follow up continued for a minimum of 18 months with a mean of 50.1 +/- 16.8 
months.  At one month, a TEE, a TTE, and a TC-D were performed.  A holter monitor 
was used with a subsequent clinical visit.  At 6 months, a TTE was performed with a 
clinic visit and a MIDAS assessment and then a TEE was performed if a shunt was 
detected.  At 12 months, a TTE was performed along with a clinical visit and a MIDAS 
assessment.  The MIDAS assessment was continued yearly thereafter.  Closure of the 
PFO was complete in 91.2% with a persistent small shunt in 7 participants.  After 
contacting the authors of this study, it was revealed that almost 2/3 of these participants 
were from the Rigatelli et al 2010 study9 and were followed up for a longer period of 
time.10 
Chessa et al 
 This prospective observational study11 included 42 participants, 33 female, 9 male 
and 28 of the total with aura.  The average age was 39 +/- 11.2 years.  The setting was 
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performed in a single center.  Percutaneous PFO closure was performed, but details nor 
type of device were included in the study.  Participants were given clopidogrel 75 mg 
plus ASA 150 mg for 30 days, then ASA 300 mg alone for five months thereafter.  No 
comparisons or sham procedures were performed.  Inclusion criteria consisted of adults 
with migraine headaches, migraine with or without aura, migraine with TIA, migraine 
with ischemic brain lesions, a long history of unsuccessful medical treatment with 
various drugs, RLS consistent with PFO and prior neurologic, hematologic and 
cardiologic assessments.11 
 The primary outcome resulted in resolution of migraine headaches in 11 
participants.  Secondary outcomes resulted in decrease in frequency of migraines in 22 
participants and decrease in aura from 8.8 to 7.5.  The Migraine Severity Score (MSS) 
assessment was given prior and post procedure, which indicated a global score of 8.3 to 
4.3 (P value = 0.00001), intensity 2.6 to 1.2 (P value = 0.00001), duration 2.5 to 1.3 (P 
value = 0.00001), frequency 2.6 to 1.3 (P value = 0.0001) and aura 8.3 to 4.3 (P value = 
0.00001).  Overall, 78% of participants were cured or showed significant improvement.  
No major or adverse complications were noted.  Follow up lasted 6 months, at which 
time a TC-D was performed.  Closure of the PFO was complete in 73% with a residual 
shunt remaining in 10 participants.  The MSS assessment was performed prior to the 
procedure and again at 6 months post procedure.11 
Wahl et al 
 This retrospective observational study12 included 17 participants, 13 female, 4 
male and 14 total with aura.  The average age of enrolled participants was 44 +/- 12 
years.  The location and setting was not specified.  The intervention consisted of PFO 
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closure using the Amplatzer PFO Occluder, guided by fluoroscopy.  After the procedure, 
participants were given ASA 100 mg daily for five months and clopidogrel 75 mg daily 
for one month.  No comparison or sham procedure was performed.  Inclusion criteria 
consisted of adults with migraine headaches with or without aura refractory to medical 
treatment and exhibiting RLS consistent with a diagnosis of PFO.12 
 The primary outcome was migraine headache cessation, which occurred in 4 of 
the 17 participants.  Secondary outcomes included improvement in migraine 
symptomology, which occurred in 8 participants with a 75% reduction in 3 participants, 
50% reduction in 3 participants and 25% reduction in 2 participants.  Migraines were 
unchanged in 5 participants.  Migraine with aura improved from 82% to 24% (P = 0.002).  
No patient had worsening of symptoms.  Data was collected through a questionnaire 
developed with criteria from the International Headache Society (IHS) along with self-
rating of improving or worsening symptoms.  No major or adverse complications 
occurred.12 
No patient was lost to follow up.  At 6 months post procedure, contrast TEE after 
Valsalva maneuver was performed.  This indicated complete PFO closure in 16 
participants with a minimal residual shunt in one.  Follow up continued for up to 6 years, 
mean 2.7 +/- 1.5 years.  The IHS questionnaire was given both before and after the 
procedure.12 
DISCUSSION 
 In patients with a PFO and migraine HA refractory to medical treatment, does 
percutaneous closure of the PFO reduce the frequency, duration and intensity of migraine 
headaches?  Even though the four observational studies9-12 proved some benefit to 
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percutaneous PFO closure in patients refractory to medical treatment, the only RCT8 
performed concluded no substantial benefit.  Thus, PFO closure is not recommended for 
treatment of migraine at this time.  There are many limitations to all the studies involved.  
More RCTs are needed before recommending this procedure to patients fitting the 
inclusion criteria.  Based on the results of the studies,8-12 there may be a more significant 
prognosis of migraine headache resolution after PFO closure with the presence of aura. 
Limitations 
 Since four of the five included studies are observational studies,9-12 they are 
limited due to the fact that there is no blinding or control groups.  There was a high risk 
of selection bias in the Chessa et al11 and both Rigatelli et al studies9,10 due to operations 
being conducted within a single center.  The Wahl et al study12 was retrospective and thus 
had potential for bias.  All the studies were indirect in that they consisted of relatively 
small sample sizes, less than 100 participants.  The Wahl et al study12 in particular was 
conducted with a very small sample with only 17 participants.  It is noteworthy that the 
Rigatelli et al 2010 study9 was conducted before the Rigatteli et al 2012 study,10 and 
many of the participants were common to both trials while concluding with the same 
results.  This in itself may increase the validity of each study.  There was inconsistency in 
the Rigatelli et al 2010 study9 because of the difference in MIDAS classes of the PFO 
closure group and medical treatment group, the latter, classes 1-2 and the former, classes 
3-4.  Thus, only the more severe group received PFO closure and is a serious limitation. 
The only randomized controlled trial8 also had limitations, including limited 
follow up, failure to include appropriate secondary endpoints and inclusion of only very 
severe migraine patients.  There may have been more conclusive results if the follow up 
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had been longer than 6 months.  The primary endpoint measured cessation of migraine 
headaches, but other secondary endpoints should have been included as well, such as 
reduction in frequency, duration and intensity of migraines.  The researchers included 
severe migraine patients only, having headaches five or more times per month, seven 
headache-free days per month, refractory to medication and a moderate to large RLS.  
What about those migraine patients with headaches less than 5 times per month or more 
than seven headache-free days per month or with a mild RLS?  The benefit of PFO 
closure may possibly be noticed if treated earlier, before progression to severe migraine 
headaches.  There also seems to be a serious ethical question presented by the sham 
procedure, although an ethics committee did approve the trial, since general anesthetic 
and other invasive procedures were conducted without benefit to the sham group. 
Other limitations to the studies addressed in this systematic review are inclusion 
criteria for reasons other than just migraine and PFO.  These include cryptogenic stroke, 
TIA, paradoxical embolism, ischemic brain lesions, etc.9-11  Clopidogrel plus ASA given 
either pre or post procedure may have played a role in improvement of migraine 
symptomology.8,11-12 
Recommendations and Improvements 
 Because future studies will be needed for a more conclusive result as to 
improvement in migraine symptomology after percutaneous PFO closure, there are 
certain recommendations that could improve the quality and validity, while reducing the 
bias of future study results.  There is potential for recall bias because of the self-reporting 
headache diaries by enrolled participants.  Randomized controlled trials with sham 
procedure will be necessary, as well as allocation concealment and blinding.  A larger 
17 
 
number of participants will need to be enrolled in these RCTs.  In addition to migraine 
cessation as endpoint measurement,8 frequency, duration and intensity of migraines 
should also be measured and compared at pre and post procedure using an effective 
assessment such as the MIDAS.   
It was shown in the MIST trial8 that 6 months was not long enough for follow up.  
That was also shown in the second Rigatelli et al trial10 which used 2/3 of the same 
participants in order to have a longer follow up.  No specific length is recommended, 
however longer follow up may prove more accurate results.  Inclusion criteria must only 
consist of presence of migraine headaches in conjunction with PFO and must not include 
other reasons for PFO closure, most especially paradoxical embolism or cryptogenic 
stroke.  Lastly, all enrolled participants in said future studies must be proven to be 
refractory to most migraine medical treatments including both prophylactic and acute 
medications.  Trials such as these are already underway in the United States, Canada and 
Europe with results expected in the near future.  These trials include, but are not limited 
to, PRIMA15 and PREMIUM.16 
CONCLUSION 
 Based on the four observational studies9-12 and one RCT8 that seek to measure 
migraine symptomology after percutaneous PFO closure in patients refractory to medical 
treatment, it can be concluded that there is not yet enough unbiased and valid evidence to 
recommend percutaneous PFO closure as treatment for severe refractory migraine 
headaches.  The overall quality of evidence of all the studies based on the GRADE table 
is low, thus a strong or even moderate recommendation for PFO closure cannot be given.  
Further randomized controlled trials are needed based simply on migraine and PFO to 
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show that the benefits outweigh the risks for percutaneous patent foramen ovale closure 
for the treatment of refractory migraine headaches. 
 
19 
 
References 
 
1. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine 
headache disability and health-related quality-of-life: a population-based case-control study from 
England. Cephalalgia. 2003;23:441-450. 
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of 
migraine in the United States: data from the American Migraine Study II. Headache. 201;41:646-
657. 
3. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral 
embolism in migraine with aura: a transcranial Doppler study. Neurology. 1999;52:1622-1625. 
4. Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-
to-left shunts. Clin Sci (Lond). 2001;100:215-220. 
5. Patent foramen ovale. A.D.A.M. Medical Encyclopedia. PubMed Health web site. 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002102/. Updated December 1, 2011. 
Accessed November 24, 2012. 
6. Wilmshurst P, Nightingale S. The role of cardiac and pulmonary pathology in migraine: a 
hypothesis.  Headache. 2006;46:429-434. 
7. The Grading of Recommendations Assessment, Development and Evaluation. GRADE 
working group web site. http://gradeworkinggroup.org/. Updated 2012. Accessed November 24, 
2012. 
20 
 
8. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De 
Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A. 
Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, 
double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure 
with STARFlex septal repair implant to resolve refractory migraine headache. EBM Reviews – 
Cochrane Central Register of Controlled Trials. 2008;117(11):1397-404. 
9. Rigatelli G, Dell’Avvocata F, Ronco F, Cardaioli P, Giordan M, Braggion G, Aggio S, 
Chinaglia M, Rigatelli G, Chen JP. Primary transcatheter patent foramen ovale is effective in 
improving migraine in patients with high-risk anatomic and functional characteristics for 
paradoxical embolism. Cardiovascular Interventions. 2010;3(3):282-7. 
10. Rigatelli G, Dell’Avvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S, L’Erario R, 
Chinaglia M. Improving migraine by means of primary transcatheter patent foramen ovale 
closure: long-term follow-up. American Journal of Cardiovascular Disease. 2012;2(2):89-95. 
11. Chessa M, Colombo C, Butera G, Negura D, Piazza L, Varotto L, Bussadori C, Fesslova V, 
Meola G, Carminati M. Is it too early to recommend patent foramen ovale closure for all patients 
who suffer from migraine? A single-centre study. Journal of Cardiovascular Medicine. 
2009;10(5):401-5. 
12. Wahl A, Praz F, Findling O, Nedeltchev K, Schwerzmann M, Tai T, Windecker S, Mattle HP, 
Meier B. Percutaneous closure of patent foramen ovale for migraine headaches refractory to 
medical treatment. Catheterization & Cardiovascular Interventions. 2009;74(1)124-9. 
13. Butera G, Biondi-Zoccai G, Carminati M, Caputi L, Usai S, Bussone G, Meola G, Bibiana 
Delogu A, Sheiban I, Sangiorgi G. Systematic Review and Meta-Analysis of Currently Available 
21 
 
Clinical Evidence on Migraine and Patent Foramen Ovale Percutaneous Closure: Much Ado 
About Nothing? Catheterization and Cardiovascular Interventions. 2010;75:494-504. 
14. Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a 
quantitative systematic review. Cephalalgia. 2008;28:531-540. 
15. Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura – A Randomized 
Prospective Study (PRIMA trial). U.S. National Institutes of Health Clinical Trials web 
site. http://clinicaltrials.gov/show/NCT00505570. Updated March 21, 2012. Accessed 
December 4, 2012. 
16. Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction 
in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical 
Management (PREMIUM trial). U.S. National Institutes of Health Clinical Trials web 
site. http://clinicaltrials.gov/show/NCT00355056. Updated April 19, 2012. Accessed 
December 4, 2012. 
22 
 
TABLE 1 GRADE Quality of Assessment and Summary of Findings 
Quality Assessment Summary of Findings 
 Downgrade Criteria  Number of Patients 
Quality 
Importance No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication bias 
likely Study PFO closure 
Sham or 
medical tx or no 
PFO closure 
CESSATION of migraine headache 
3 
 
1 RCT 
2 Observational 
 Very serious 
limitationsa 
Serious 
indirectnessb 
No serious 
imprecisionc 
No serious 
inconsistencies No bias likely
 
MIST 3/74 3/73 
Low Critical Chessa et al 11/42 - 
Wahl et al 4/17 - 
Reduction in FREQUENCY of migraine headache 
4 4 Observational Very serious limitationsa 
Serious 
indirectnessb 
No serious 
imprecision 
Serious 
inconsistenciesd No bias likely 
Rigatelli et al 2010 40/40 MIDAS 0/46 
Very Low Critical 
Rigatelli et al 2012 70/80 MIDAS - 
Chessa et al   22/42 - 
Wahl et al 8/17 - 
Reduction in DURATION of migraine headache 
2 2 Observational Very Serious limitationsa 
Serious 
indirectnessb 
No serious 
imprecision 
No serious 
inconsistencies No bias likely 
Chessa et al   2.5 to 1.3 MSS - 
Very Low Important 
Wahl et al Not significantly altered - 
Reduction in INTENSITY of migraine headache 
4 4 Observational Very serious limitationsa 
Serious 
indirectnessb 
No serious 
imprecision 
Serious 
inconsistenciesd No bias likely 
Rigatelli et al 2010 40/40 MIDAS 0/46 
Very Low Important 
Rigatelli et al 2012 70/80 MIDAS - 
Chessa et al   2.6 to 1.2 MSS - 
Wahl et al 9 +/- 1 to 5 +/- 3 - 
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Cessation of migraine with AURA 
4 4 Observational Very Serious limitationsa 
Serious 
indirectnessb 
No serious 
imprecision 
Serious 
inconsistenciesd No bias likely 
Rigatelli et al 2010 32/32 0/10 
Very low Important 
Rigatelli et al 2012 61/63 - 
Chessa et al   7/28 - 
Wahl et al 4/14 - 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation 
aHigh risk for selection bias in both Rigatelli et al (2010 and 2012) studies and the Chessa et al study because they were conducted in a single center.  No control groups used in the Rigatelli et al 2012, Chessa et al and Wahl el al studies.  Only a quasi-
control group was used in the Rigatelli et al 2010 study.  The Wahl et al study was a retrospective study. 
bSmall sample sizes (less than 100) in the Rigatelli et al 2010, Rigatelli et al 2012, Chessa et al and Wahl et al studies. Indirect comparison between PFO closure and medical treatment groups in the Rigatelli et al 2010 study. 
cResults of the MIST indicate no appreciable benefit or harm. 
dPFO closure group (MIDAS classes 3-4) prognostically different from medical treatment group (MIDAS classes 1-2) in the Rigatelli et al 2010 study. 
